Search research articles
Contact Us
Filters
Showing results (191-200 of 284) with videos related to
Page
of 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
February 9, 2019
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
Chiara Cremolini, Federica Marmorino, Francesca Bergamo, et al.
JAMA Oncology
|
November 27, 2018
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini, Daniele Rossini, Emanuela Dell'Aquila, et al.
Oncotarget
|
March 1, 2018
<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Chiara Cremolini, Marzia Del Re, Carlotta Antoniotti, et al.
JCO Precision Oncology
|
November 10, 2022
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases
Federica Marmorino, Michele Prisciandaro, Mirella Giordano, et al.
Scientific Reports
|
March 1, 2019
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
Giovanni Randon, Giovanni Fucà, Daniele Rossini, et al.
JAMA Network Open
|
April 9, 2024
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial
Davide Ciardiello, Erika Martinelli, Teresa Troiani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
CtDNA detection with low-pass whole genome bisulfite sequencing in RAS wild-type metastatic colorectal cancer: an exploratory objective of the VALENTINO trial
Paolo Manca, Marta Paoli, Francesca Galardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors
Claire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
Carlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, et al.
Page
of 29
Search research articles
Search
Showing results (191-200 of 284) with videos related to
Sort By:
Page
of 29
European Journal of Cancer (Oxford, England : 1990)
|
February 9, 2019
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
Chiara Cremolini, Federica Marmorino, Francesca Bergamo, et al.
JAMA Oncology
|
November 27, 2018
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini, Daniele Rossini, Emanuela Dell'Aquila, et al.
Oncotarget
|
March 1, 2018
<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Chiara Cremolini, Marzia Del Re, Carlotta Antoniotti, et al.
JCO Precision Oncology
|
November 10, 2022
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases
Federica Marmorino, Michele Prisciandaro, Mirella Giordano, et al.
Scientific Reports
|
March 1, 2019
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
Giovanni Randon, Giovanni Fucà, Daniele Rossini, et al.
JAMA Network Open
|
April 9, 2024
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial
Davide Ciardiello, Erika Martinelli, Teresa Troiani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
CtDNA detection with low-pass whole genome bisulfite sequencing in RAS wild-type metastatic colorectal cancer: an exploratory objective of the VALENTINO trial
Paolo Manca, Marta Paoli, Francesca Galardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors
Claire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
Carlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, et al.
Page
of 29